Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

PATH Malaria Vaccine Initiative

Quote from the article: Without adapting JCA to include assessment of real-world data and broader benefits, vaccines may be undervalued

Is Joint Clinical Assessment (JCA) appropriate for assessing the broader value of vaccines?

By Emily Morton-West

Amiculum

- PMLiVE

Novartis reports primary endpoint reached in phase 3 malaria trial

The treatment demonstrated non-inferiority to current standard of care

- PMLiVE

A Call to Action: Bridging the Adult Immunization Divide

Over the past few years, as new diseases have emerged or reemerged, a host of new vaccines have become available while many others are in the pipeline. For older adults,...

Medscape Education

- PMLiVE

Sanofi and Kling Bio partner to accelerate discovery of neutralising antibodies

The alliance will centre on Kling’s B cell immortalisation and screening platform Kling-Select

- PMLiVE

Prostate cancer blood test with ‘unprecedented accuracy’ cuts biopsies by 50%

There is currently no national screening programme for prostate cancer in the UK

dengue fever mosquito

Positive efficacy results for R21/Matrix-M malaria vaccine published in The Lancet

R21 was added to the World Health Organization's list of prequalified vaccines in December

- PMLiVE

World Health Organization adds second malaria vaccine to prequalification list

The addition is expected to result in sufficient malaria vaccine supply for children

- PMLiVE

WHO recommends second malaria vaccine for children

The addition of R21/Matrix-M to the organisation’s list is expected to result in sufficient malaria vaccine supply

- PMLiVE

GSK discovers strain of bacterium that stops malaria transmission

It is hoped that the discovery could contribute to the eradication of the disease

Video: Strategic engagement case study

Supporting the launch of a global vaccine with a programme of market research and strategic insights

Inizio

- PMLiVE

Novartis and MMV to advance new malaria drug combination to phase 3 study

The announcement comes as the threat of resistance to current malaria treatments grows

- PMLiVE

WHO launches R&D efforts to identify pathogens that could cause future pandemics

Over 300 scientists will convene to discuss over 25 virus and bacteria, including ‘Disease X’

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links